RHYTHM PHARMACEUTICALS, INC. (RYTM) Scorecard
- 2026-Q2: Total return Win; Revenue growth Win; EPS growth Lose.
- 2026-Q1: Total return Lose; Revenue growth Win; EPS growth Lose.
- 2025-Q4: Total return Win; Revenue growth Win; EPS growth Lose.
- 2025-Q3: Total return Win; Revenue growth Win; EPS growth Lose.
37/120
All 120 Win/Lose results shown below
Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
Trailing 1 year (4 quarters): 7 wins, 5 lossesLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q22/3 |
WinRYTM / S&P 27.66% / 15.20% |
WinRYTM / S&P 53.51% / 15.00% |
LoseRYTM / S&P 3.32% / 50.40% |
| 2026-Q11/3 |
LoseRYTM / S&P -18.75% / -4.33% |
WinRYTM / S&P 58.67% / 11.30% |
LoseRYTM / S&P 11.39% / 27.70% |
| 2025-Q42/3 |
WinRYTM / S&P 5.99% / 2.65% |
WinRYTM / S&P 45.83% / 9.00% |
LoseRYTM / S&P -28.51% / 13.40% |
| 2025-Q32/3 |
WinRYTM / S&P 59.82% / 8.12% |
WinRYTM / S&P 54.92% / 4.61% |
LoseRYTM / S&P -28.41% / 13.45% |
| 2025-Q22/3 |
WinRYTM / S&P 19.29% / 10.94% |
WinRYTM / S&P 53.55% / 4.83% |
LoseRYTM / S&P -30.96% / 10.63% |
| 2025-Q11/3 |
LoseRYTM / S&P -5.38% / -4.27% |
WinRYTM / S&P 48.88% / 4.98% |
LoseRYTM / S&P -39.31% / 10.57% |
| 2024-Q43/3 |
WinRYTM / S&P 6.85% / 2.41% |
WinRYTM / S&P 68.06% / 5.25% |
WinRYTM / S&P 35.94% / 6.15% |
| 2024-Q33/3 |
WinRYTM / S&P 27.59% / 5.89% |
WinRYTM / S&P 81.55% / 5.89% |
WinRYTM / S&P 33.64% / 6.11% |
| 2024-Q22/3 |
LoseRYTM / S&P -5.24% / 4.28% |
WinRYTM / S&P 132.57% / 5.38% |
WinRYTM / S&P 33.33% / 5.12% |
| 2024-Q12/3 |
LoseRYTM / S&P -5.74% / 10.56% |
WinRYTM / S&P 173.52% / 5.71% |
WinRYTM / S&P 38.62% / 5.59% |
| 2023-Q42/3 |
WinRYTM / S&P 100.52% / 11.69% |
WinRYTM / S&P 227.56% / 6.81% |
LoseRYTM / S&P -7.78% / 7.78% |
| 2023-Q32/3 |
WinRYTM / S&P 39.02% / -3.27% |
WinRYTM / S&P 271.94% / 7.52% |
LoseRYTM / S&P -9.75% / -5.03% |
| 2023-Q22/3 |
LoseRYTM / S&P -7.57% / 8.74% |
WinRYTM / S&P 226.38% / 9.50% |
WinRYTM / S&P -6.57% / -8.57% |
| 2023-Q12/3 |
LoseRYTM / S&P -38.74% / 7.50% |
WinRYTM / S&P 627.94% / 10.77% |
WinRYTM / S&P 0.91% / -15.69% |
| 2022-Q43/3 |
WinRYTM / S&P 18.86% / 7.56% |
WinRYTM / S&P 649.46% / 11.88% |
WinRYTM / S&P 155.15% / -17.99% |
| 2022-Q31/3 |
WinRYTM / S&P 490.36% / -4.88% |
LoseRYTM / S&P RYTM unavailable / 13.47% |
LoseRYTM / S&P RYTM unavailable / -1.41% |
| 2022-Q20/3 |
LoseRYTM / S&P -63.98% / -16.10% |
LoseRYTM / S&P RYTM unavailable / 13.71% |
LoseRYTM / S&P RYTM unavailable / 11.04% |
| 2022-Q11/3 |
WinRYTM / S&P 15.43% / -4.60% |
LoseRYTM / S&P RYTM unavailable / 15.97% |
LoseRYTM / S&P RYTM unavailable / 42.23% |
| 2021-Q40/3 |
LoseRYTM / S&P -23.58% / 11.03% |
LoseRYTM / S&P RYTM unavailable / 15.00% |
LoseRYTM / S&P RYTM unavailable / 96.40% |
| 2021-Q30/3 |
LoseRYTM / S&P -33.30% / 0.58% |
LoseRYTM / S&P RYTM unavailable / 10.77% |
LoseRYTM / S&P RYTM unavailable / 69.42% |
| 2021-Q20/3 |
LoseRYTM / S&P -7.95% / 8.55% |
LoseRYTM / S&P RYTM unavailable / 6.58% |
LoseRYTM / S&P RYTM unavailable / 51.81% |
| 2021-Q10/3 |
LoseRYTM / S&P -28.46% / 6.17% |
LoseRYTM / S&P RYTM unavailable / -1.06% |
LoseRYTM / S&P RYTM unavailable / 7.39% |
| 2020-Q41/3 |
WinRYTM / S&P 37.19% / 12.15% |
LoseRYTM / S&P RYTM unavailable / -3.72% |
LoseRYTM / S&P RYTM unavailable / -33.42% |
| 2020-Q30/3 |
LoseRYTM / S&P -2.83% / 8.93% |
LoseRYTM / S&P RYTM unavailable / -2.04% |
LoseRYTM / S&P RYTM unavailable / -27.10% |
| 2020-Q21/3 |
WinRYTM / S&P 46.52% / 20.54% |
LoseRYTM / S&P RYTM unavailable / -0.46% |
LoseRYTM / S&P RYTM unavailable / -27.11% |
| 2020-Q10/3 |
LoseRYTM / S&P -33.71% / -19.60% |
LoseRYTM / S&P RYTM unavailable / 3.47% |
LoseRYTM / S&P RYTM unavailable / -14.75% |
| 2019-Q40/3 |
LoseRYTM / S&P 6.35% / 9.07% |
LoseRYTM / S&P RYTM unavailable / 5.36% |
LoseRYTM / S&P RYTM unavailable / 2.99% |
| 2019-Q30/3 |
LoseRYTM / S&P -1.86% / 1.70% |
LoseRYTM / S&P RYTM unavailable / 5.02% |
LoseRYTM / S&P RYTM unavailable / 0.21% |
| 2019-Q20/3 |
LoseRYTM / S&P -19.74% / 4.30% |
LoseRYTM / S&P RYTM unavailable / 6.64% |
LoseRYTM / S&P RYTM unavailable / 8.65% |
| 2019-Q10/3 |
LoseRYTM / S&P 1.97% / 13.65% |
LoseRYTM / S&P RYTM unavailable / 8.12% |
LoseRYTM / S&P RYTM unavailable / 14.29% |
| 2018-Q41/3 |
WinRYTM / S&P -7.85% / -13.52% |
LoseRYTM / S&P RYTM unavailable / 9.05% |
LoseRYTM / S&P RYTM unavailable / 18.23% |
| 2018-Q30/3 |
LoseRYTM / S&P -6.69% / 7.71% |
LoseRYTM / S&P RYTM unavailable / 10.21% |
LoseRYTM / S&P RYTM unavailable / 19.06% |
| 2018-Q21/3 |
WinRYTM / S&P 57.09% / 3.43% |
LoseRYTM / S&P RYTM unavailable / 9.03% |
LoseRYTM / S&P RYTM unavailable / 14.46% |
| 2018-Q10/3 |
LoseRYTM / S&P -31.52% / -0.76% |
LoseRYTM / S&P RYTM unavailable / 7.68% |
LoseRYTM / S&P RYTM unavailable / 12.46% |
| 2017-Q40/3 |
LoseRYTM / S&P RYTM unavailable / 6.64% |
LoseRYTM / S&P RYTM unavailable / 7.03% |
LoseRYTM / S&P RYTM unavailable / 13.82% |
| 2017-Q30/3 |
LoseRYTM / S&P RYTM unavailable / 4.48% |
LoseRYTM / S&P RYTM unavailable / 5.68% |
LoseRYTM / S&P RYTM unavailable / 17.57% |
| 2017-Q20/3 |
LoseRYTM / S&P RYTM unavailable / 3.09% |
LoseRYTM / S&P RYTM unavailable / 4.83% |
LoseRYTM / S&P RYTM unavailable / 17.74% |
| 2017-Q10/3 |
LoseRYTM / S&P RYTM unavailable / 6.07% |
LoseRYTM / S&P RYTM unavailable / 3.67% |
LoseRYTM / S&P RYTM unavailable / 13.32% |
| 2016-Q40/3 |
LoseRYTM / S&P RYTM unavailable / 3.82% |
LoseRYTM / S&P RYTM unavailable / 2.09% |
LoseRYTM / S&P RYTM unavailable / 7.05% |
| 2016-Q30/3 |
LoseRYTM / S&P RYTM unavailable / 3.85% |
LoseRYTM / S&P RYTM unavailable / 0.20% |
LoseRYTM / S&P RYTM unavailable / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | RYTM total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 9.09% | 20.78% |
| Annualized return | 9.09% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | RYTM total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 733.56% | 83.14% |
| Annualized return | 52.82% | 12.86% |
10Y · 2017-10-09 to 2026-08-27
| Metric | RYTM total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 358.00% | 319.30% |
| Annualized return | 16.44% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |